JP2015524483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524483A5 JP2015524483A5 JP2015526717A JP2015526717A JP2015524483A5 JP 2015524483 A5 JP2015524483 A5 JP 2015524483A5 JP 2015526717 A JP2015526717 A JP 2015526717A JP 2015526717 A JP2015526717 A JP 2015526717A JP 2015524483 A5 JP2015524483 A5 JP 2015524483A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- substituted
- thiadiazol
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 136
- 125000003545 alkoxy group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 10
- -1 poly (alkylene glycol Chemical group 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 230000004900 autophagic degradation Effects 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- LQHONOCAMPXWOW-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3-thiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3SC=CN=3)=CC=2)=C1 LQHONOCAMPXWOW-UHFFFAOYSA-N 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- METQSAABMLHWQI-UHFFFAOYSA-N (4-chlorophenyl)-[4-(1,3,4-thiadiazol-2-ylamino)phenyl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C(C=C1)=CC=C1NC1=NN=CS1 METQSAABMLHWQI-UHFFFAOYSA-N 0.000 claims description 2
- POVLEEZLVJLEBQ-UHFFFAOYSA-N 2-[5-[[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]amino]-1,3,4-thiadiazol-2-yl]ethanol Chemical compound S1C(CCO)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 POVLEEZLVJLEBQ-UHFFFAOYSA-N 0.000 claims description 2
- USWIJCHWKRASSV-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-N-(1,3,4-thiadiazol-2-yl)cyclohexa-1,5-diene-1,4-diamine Chemical compound ClC1=CC=C(C=C1)C1(CC=C(C=C1)NC=1SC=NN1)N USWIJCHWKRASSV-UHFFFAOYSA-N 0.000 claims description 2
- IHJCOTNOGPJEGS-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-N-(1,3,4-thiadiazol-2-yl)cyclohexa-1,5-diene-1,4-diamine Chemical compound ClC1=C(C=C(C=C1)C1(CC=C(C=C1)NC=1SC=NN1)N)C(F)(F)F IHJCOTNOGPJEGS-UHFFFAOYSA-N 0.000 claims description 2
- QBPIQIZDOMKZBO-UHFFFAOYSA-N 5-(aminomethyl)-n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound S1C(CN)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 QBPIQIZDOMKZBO-UHFFFAOYSA-N 0.000 claims description 2
- YHWARMRGGTVWMO-UHFFFAOYSA-N 5-(aziridin-1-ylmethyl)-n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC(S1)=NN=C1CN1CC1 YHWARMRGGTVWMO-UHFFFAOYSA-N 0.000 claims description 2
- TWVGPBVYAFWOKG-UHFFFAOYSA-N 5-bromo-n-[4-[3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)C=2C=CC(NC=3SC(Br)=NN=3)=CC=2)=C1 TWVGPBVYAFWOKG-UHFFFAOYSA-N 0.000 claims description 2
- HKUJIISFLUFFCV-UHFFFAOYSA-N [4-chloro-3-(trifluoromethyl)phenyl]-[4-(1,3,4-thiadiazol-2-ylamino)phenyl]methanone Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(C(=O)C=2C=CC(NC=3SC=NN=3)=CC=2)=C1 HKUJIISFLUFFCV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- GUNNOKLWFBJUQO-UHFFFAOYSA-N n-[2-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpyrimidin-5-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2N=CC(NC=3SC=NN=3)=CN=2)=C1 GUNNOKLWFBJUQO-UHFFFAOYSA-N 0.000 claims description 2
- KXSGSZSNBGOCDY-UHFFFAOYSA-N n-[3-[4-chloro-3-(trifluoromethyl)phenyl]sulfonyl-1,2,4-triazin-6-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2N=NC(NC=3SC=NN=3)=CN=2)=C1 KXSGSZSNBGOCDY-UHFFFAOYSA-N 0.000 claims description 2
- TXNOSKGLWXEJOQ-UHFFFAOYSA-N n-[4-(2-chloro-4-fluorophenyl)sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound ClC1=CC(F)=CC=C1S(=O)(=O)C(C=C1)=CC=C1NC1=NN=CS1 TXNOSKGLWXEJOQ-UHFFFAOYSA-N 0.000 claims description 2
- QWAUXCCXJBUDOV-UHFFFAOYSA-N n-[4-(4-chlorophenoxy)phenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1OC(C=C1)=CC=C1NC1=NN=CS1 QWAUXCCXJBUDOV-UHFFFAOYSA-N 0.000 claims description 2
- JJBRYZUGWJJTPU-UHFFFAOYSA-N n-[4-(4-fluorophenyl)sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C(C=C1)=CC=C1NC1=NN=CS1 JJBRYZUGWJJTPU-UHFFFAOYSA-N 0.000 claims description 2
- SZGLXKSNLYOORR-UHFFFAOYSA-N n-[4-[3-(trifluoromethoxy)phenyl]sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC(S(=O)(=O)C=2C=CC(NC=3SC=NN=3)=CC=2)=C1 SZGLXKSNLYOORR-UHFFFAOYSA-N 0.000 claims description 2
- RHSIJRLJXARZFB-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenoxy]phenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(OC=2C=CC(NC=3SC=NN=3)=CC=2)=C1 RHSIJRLJXARZFB-UHFFFAOYSA-N 0.000 claims description 2
- PHYYVLXFAQCOLF-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonyl-3-fluorophenyl]-1,3,4-thiadiazol-2-amine Chemical compound C=1C=C(S(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)C(F)=CC=1NC1=NN=CS1 PHYYVLXFAQCOLF-UHFFFAOYSA-N 0.000 claims description 2
- YVUIQHKJPBSQSU-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3,4-oxadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3OC=NN=3)=CC=2)=C1 YVUIQHKJPBSQSU-UHFFFAOYSA-N 0.000 claims description 2
- LWGDIODWJORJOC-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3SC=NN=3)=CC=2)=C1 LWGDIODWJORJOC-UHFFFAOYSA-N 0.000 claims description 2
- SZOPGUATBWMHNR-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1h-1,2,4-triazol-5-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3NN=CN=3)=CC=2)=C1 SZOPGUATBWMHNR-UHFFFAOYSA-N 0.000 claims description 2
- FFPBFHRJGZTMQU-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1h-imidazol-5-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3NC=NC=3)=CC=2)=C1 FFPBFHRJGZTMQU-UHFFFAOYSA-N 0.000 claims description 2
- AXWHUZXBRSKCLL-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-1h-pyrrol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC=3NC=CC=3)=CC=2)=C1 AXWHUZXBRSKCLL-UHFFFAOYSA-N 0.000 claims description 2
- URTSUAFRXCZONN-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]-2h-tetrazol-5-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2C=CC(NC3=NNN=N3)=CC=2)=C1 URTSUAFRXCZONN-UHFFFAOYSA-N 0.000 claims description 2
- SKFKQHGEQGJBPF-UHFFFAOYSA-N n-[4-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]phenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(CC=2C=CC(NC=3SC=NN=3)=CC=2)=C1 SKFKQHGEQGJBPF-UHFFFAOYSA-N 0.000 claims description 2
- JGXKXZOVOZYZTI-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC1=NN=CS1 JGXKXZOVOZYZTI-UHFFFAOYSA-N 0.000 claims description 2
- IQIARBSSAQBFHI-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-5-(morpholin-4-ylmethyl)-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC(S1)=NN=C1CN1CCOCC1 IQIARBSSAQBFHI-UHFFFAOYSA-N 0.000 claims description 2
- HXQHDPILLFXWCT-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-5-(piperidin-1-ylmethyl)-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC(S1)=NN=C1CN1CCCCC1 HXQHDPILLFXWCT-UHFFFAOYSA-N 0.000 claims description 2
- CXKMZZFUCHIDLF-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-5-[(4-methylpiperazin-1-yl)methyl]-1,3,4-thiadiazol-2-amine Chemical compound C1CN(C)CCN1CC(S1)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 CXKMZZFUCHIDLF-UHFFFAOYSA-N 0.000 claims description 2
- HOQMPQSKSOMKEF-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-5-[(4-methylsulfonylpiperazin-1-yl)methyl]-1,3,4-thiadiazol-2-amine Chemical compound C1CN(S(=O)(=O)C)CCN1CC(S1)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 HOQMPQSKSOMKEF-UHFFFAOYSA-N 0.000 claims description 2
- YVDXBXAATHPPEW-UHFFFAOYSA-N n-[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]-5-[(dimethylamino)methyl]-1,3,4-thiadiazol-2-amine Chemical compound S1C(CN(C)C)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 YVDXBXAATHPPEW-UHFFFAOYSA-N 0.000 claims description 2
- SCKSIULALHNVKP-UHFFFAOYSA-N n-[5-(4-fluorophenyl)sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC1=NN=CS1 SCKSIULALHNVKP-UHFFFAOYSA-N 0.000 claims description 2
- KYUNDAOKBURETM-UHFFFAOYSA-N n-[5-[4-(trifluoromethoxy)phenyl]sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC1=NN=CS1 KYUNDAOKBURETM-UHFFFAOYSA-N 0.000 claims description 2
- WFXZNLXXEPXNCW-UHFFFAOYSA-N n-[5-[4-(trifluoromethyl)phenyl]sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)C(N=C1)=CN=C1NC1=NN=CS1 WFXZNLXXEPXNCW-UHFFFAOYSA-N 0.000 claims description 2
- CYNPWXCNCPZFOB-UHFFFAOYSA-N n-[5-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpyrazin-2-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2N=CC(NC=3SC=NN=3)=NC=2)=C1 CYNPWXCNCPZFOB-UHFFFAOYSA-N 0.000 claims description 2
- SDMIDNGLYTZDHC-UHFFFAOYSA-N n-[6-[4-chloro-3-(trifluoromethyl)phenyl]sulfonyl-1,2,4,5-tetrazin-3-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2N=NC(NC=3SC=NN=3)=NN=2)=C1 SDMIDNGLYTZDHC-UHFFFAOYSA-N 0.000 claims description 2
- QMXJMPRWYDCXCG-UHFFFAOYSA-N n-[6-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpyridin-3-yl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)C=2N=CC(NC=3SC=NN=3)=CC=2)=C1 QMXJMPRWYDCXCG-UHFFFAOYSA-N 0.000 claims description 2
- USANJCUYKQTNCU-UHFFFAOYSA-N n-[[5-[[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]amino]-1,3,4-thiadiazol-2-yl]methyl]acetamide Chemical compound S1C(CNC(=O)C)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 USANJCUYKQTNCU-UHFFFAOYSA-N 0.000 claims description 2
- PUCFTQBPVTZKNA-UHFFFAOYSA-N n-[[5-[[5-(4-chlorophenyl)sulfonylpyrazin-2-yl]amino]-1,3,4-thiadiazol-2-yl]methyl]methanesulfonamide Chemical compound S1C(CNS(=O)(=O)C)=NN=C1NC1=CN=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=N1 PUCFTQBPVTZKNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KAQZQFPYKRJGSK-UHFFFAOYSA-N n-[4-[3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)C=2C=CC(NC=3SC=NN=3)=CC=2)=C1 KAQZQFPYKRJGSK-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 0 **C1(*)C=CCCCCC(*C(*=*C(*c2cc(*)c(*)c(*)c2*)=**)=C)CCC1 Chemical compound **C1(*)C=CCCCCC(*C(*=*C(*c2cc(*)c(*)c(*)c2*)=**)=C)CCC1 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FUSFWUFSEJXMRQ-UHFFFAOYSA-N 2-bromo-1,1-dimethoxyethane Chemical compound COC(CBr)OC FUSFWUFSEJXMRQ-UHFFFAOYSA-N 0.000 description 1
- SRCGKJZZVWYIGT-UHFFFAOYSA-N N-[4-(4-chlorophenyl)sulfonylphenyl]-5-[(4-methylsulfonylpiperazin-1-yl)methyl]-1,3,4-thiadiazol-2-amine Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(C=C1)NC=1SC(=NN1)CN1CCN(CC1)S(=O)(=O)C SRCGKJZZVWYIGT-UHFFFAOYSA-N 0.000 description 1
- GIYUOZBEUIMMJV-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylphenyl]thiourea Chemical compound C1=CC(NC(=S)N)=CC=C1S(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 GIYUOZBEUIMMJV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- YUVKNKMPXOKAQO-UHFFFAOYSA-N n-[2-chloro-4-[3-(trifluoromethyl)phenyl]sulfonylphenyl]-1,3,4-thiadiazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)C=2C=C(Cl)C(NC=3SC=NN=3)=CC=2)=C1 YUVKNKMPXOKAQO-UHFFFAOYSA-N 0.000 description 1
- PILZNCSONFVBOX-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]phenyl]-1,3,4-thiadiazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(C=2C=CC(NC=3SC=NN=3)=CC=2)=C1 PILZNCSONFVBOX-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681585P | 2012-08-09 | 2012-08-09 | |
| US61/681,585 | 2012-08-09 | ||
| PCT/US2013/054200 WO2014026039A2 (en) | 2012-08-09 | 2013-08-08 | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524483A JP2015524483A (ja) | 2015-08-24 |
| JP2015524483A5 true JP2015524483A5 (enExample) | 2016-09-29 |
Family
ID=50068715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526717A Abandoned JP2015524483A (ja) | 2012-08-09 | 2013-08-08 | Ｐｉ３−キナーゼシグナリング経路の調節因子としてのアリール及びヘテロアリールで置換されたベンゼン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150197513A1 (enExample) |
| EP (1) | EP2882726A4 (enExample) |
| JP (1) | JP2015524483A (enExample) |
| CN (1) | CN104703985A (enExample) |
| CA (1) | CA2881472A1 (enExample) |
| HK (1) | HK1206331A1 (enExample) |
| MX (1) | MX2015001793A (enExample) |
| WO (1) | WO2014026039A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
| CN108947985A (zh) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | 用作自噬调节剂的化合物及其制备方法和用途 |
| US10633350B2 (en) | 2017-09-13 | 2020-04-28 | Novartis Ag | Diphenyl derivatives and uses thereof |
| AU2018359224B2 (en) | 2017-10-30 | 2023-10-05 | Neuropore Therapies, Inc. | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
| TWI903299B (zh) | 2018-03-08 | 2025-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| JP7506903B2 (ja) * | 2019-11-01 | 2024-06-27 | 日本メナード化粧品株式会社 | Ｉｌ－３７産生促進剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1476503A (en) * | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| DE3307506A1 (de) * | 1983-03-03 | 1984-09-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen |
| US20020183306A1 (en) * | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| EP1426046A4 (en) * | 2001-09-14 | 2005-11-02 | Shionogi & Co | NEW USE OF TRICYCLIC COMPOUNDS |
| US20050228031A1 (en) * | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
| US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| KR20080019213A (ko) * | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| JP2009500351A (ja) * | 2005-07-04 | 2009-01-08 | ドクター レディズ ラボラトリーズ リミテッド | Ａｍｐｋアクチベータとしてのチアゾール誘導体 |
| US9271962B2 (en) * | 2008-03-17 | 2016-03-01 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| IN2012DN00754A (enExample) * | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc |
-
2013
- 2013-08-08 WO PCT/US2013/054200 patent/WO2014026039A2/en not_active Ceased
- 2013-08-08 EP EP13828347.8A patent/EP2882726A4/en not_active Withdrawn
- 2013-08-08 HK HK15106801.9A patent/HK1206331A1/xx unknown
- 2013-08-08 CA CA2881472A patent/CA2881472A1/en not_active Abandoned
- 2013-08-08 MX MX2015001793A patent/MX2015001793A/es unknown
- 2013-08-08 JP JP2015526717A patent/JP2015524483A/ja not_active Abandoned
- 2013-08-08 CN CN201380052581.7A patent/CN104703985A/zh active Pending
- 2013-08-08 US US14/420,315 patent/US20150197513A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524483A5 (enExample) | ||
| JP2020033357A5 (enExample) | ||
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| RU2500673C2 (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| JP6294277B2 (ja) | Ｈｅｃ１活性の調節因子およびそのための方法 | |
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| RU2017122364A (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
| WO2019191624A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| JP2008513515A5 (enExample) | ||
| AU2008291921A1 (en) | Heterocyclic amides useful for the treatment of cancer and psoriasis | |
| JP2016518399A5 (enExample) | ||
| MX2009000290A (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso. | |
| KR20170094263A (ko) | Ｎａｄｐｈ 옥시다제 억제제인 아미도 티아디아졸 유도체 | |
| WO2002051442A1 (en) | Concomitant drugs | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2010516701A5 (enExample) | ||
| JP2008502614A5 (enExample) | ||
| JP2010500334A5 (enExample) | ||
| JP2018503647A5 (enExample) | ||
| SI3119782T1 (en) | COMPOUNDS 2,7-DIAZASPIRO (3.5) NONANA | |
| JP2000302680A (ja) | 脳保護剤 | |
| RU2016128365A (ru) | 5-арил-1-имино-1-оксо-[1,2,4]тиадиазины | |
| JP7035275B2 (ja) | ベンズイミダゾール化合物、及びアルツハイマー病又はハンチントン病の治療のためのその使用 | |
| CN110105286B (zh) | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 | |
| KR102873079B1 (ko) | Rna 바이러스 감염 치료를 위한 아릴-n-아릴 유도체 |